



Department of Health and Human Services
MaineCare Services, Pharmacy Unit
442 Civic Center Drive
11 State House Station
Augusta, Maine 04333-0011
Tel: (207) 287-7131; Fax: (207) 287-8601
1-866-796-2463
TTY: 1-800-423-4331

GUIDELINES FOR PROVIDING PUBLIC COMMENT TO THE MAINECARE DUR COMMITTEE

It is the intention of the State of Maine that those interested in speaking be allowed to do so in the public forum. To assure public input into the Preferred Drug List (PDL) process, the agenda for the DUR Committee will be posted on the website (www.mainearepdl.org) prior to the meeting. We realize this is a public forum; therefore, a sign-up sheet for walk-ins will be available at the door. These walk-in speakers will have their opportunity to speak in the order of sign-in after the scheduled speakers are finished.

In order to accommodate all interested parties, we ask that all speakers limit their comments to **5 minutes or less**. If you represent a drug manufacturer, we expect you to cover your individual product or entire product line in that five-minute time frame.

The Committee is interested in clinical information that may set your product apart from other products in the same PDL category. The Committee is not interested in materials intended to market your product or repetitive comments from solicited sources. We request that if a manufacturer has a concise synopsis (one side of one page) of its product and the clinical advantages of its product in comparison to other products in its PDL category, that you forward this information to Mike Ouellette at mouellette@ghsinc.com so that information can be distributed to the committee members.

Thank you for your cooperation.

SUMMARY

1. Sign up to speak.
2. Provide a concise synopsis of the product (one side of one page) and submit to mouellette@ghsinc.com or bring copies to the meeting (recommend minimum 15).
3. Speakers must provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area.
4. Limit speaking time to less than five minutes for their individual product or entire product line.
5. Direct comments toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results etc...
6. Audiovisual equipment is not allowed due to time constraints.